Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2, Recursion’s new AI supercomputer, powered by 63 with a total of 504 interconnected by NVIDIA ....
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will support the construction of foundation models across biology, chemistry, and patient outcomesTranscriptomics technology has continued to be scaled to more than 1 million transcriptomes with a whole-genome knockout transcriptomics map to be completed in the coming quartersEntered into a multi-year agreement wit...
COLUMBUS, Ohio--(BUSINESS WIRE)-- Installed Building Products, Inc. (the "Company" or "IBP") (NYSE: IBP), an industry-leading installer of insulation and complementary building products, today announced results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights (Comparisons are to Prior Year Period) Net revenue increased 5.1% to $692.9 million Installation revenue increased 5.3% to $655.9 million, as single-family and multi-family sales growth combined with sales from IBP's recent acquisitions Other revenue, which includes IBP’s manufacturing and distribution o...
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy, subject to review of IND application; expect to initiate the study by year-end Plan to present new clinical data from the ongoing NTLA-2001 Phase 1 in 2H 2024 On track to initiate the Phase 3 study of NTLA-2002 ...
Beyond Meat® Reports First Quarter 2024 Financial Results EL SEGUNDO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ: BYND) (“Beyond Meat” or “the Company”), a leader in plant-based meat, today reported financial results for its first quarter ended March 30, 2024. First Quarter 2024 Financial Highlights1 Net revenues were $75.6 million, a decrease of 18.0% year-over-year.Gross profit was $3.7 million, or gross margin of 4.9%, compared to gross profit of $6.2 million, or gross margin of 6.7%, in the year-ago period.Loss from operations was $53.5 million, or operating...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.